There’s a real difference between the two. An adrenal tumour is any growth on the adrenal gland, and most stay benign and harmless. Adrenal cancer is the rare malignant kind that grows fast and can spread. Same starting point, very different behaviour, which is why the distinction matters.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “The word tumour just means there’s a growth. It says nothing about danger. What matters is how it behaves, its size, what the scan shows, whether it’s leaking hormones. Most turn out to be quiet adenomas. Even so, none gets cleared without hormone testing first.”

It comes down to how the growth behaves, not the label on your report.

• Growth : Benign adenomas barely change, some stay put for years. Adrenocortical carcinoma is in a hurry.
• Spread : A benign one stays where it is. Cancer pushes into nearby tissue and reaches the liver, lungs or lymph nodes. That’s the real split.
• Size : Under 4 cm, usually just watched. Cross 4 cm and the cancer risk climbs, so those come out.
• Imaging : Clean edges on a CT lean benign. Ragged margins, a patchy middle, uneven density? That’s the worrying kind.

Either way a proper workup is needed, and the right adrenal tumour treatment hangs on which one it actually is.

Side by side, here’s where they part ways.

• Hormones : Plenty of benign tumours still cause trouble by pumping out cortisol or adrenaline. Benign isn’t the same as harmless.
• Symptoms : Blood pressure spikes, weight shifts, fatigue. How you feel won’t tell the two apart.
• Scans : Imaging points one way. Hormone tests, and sometimes the final pathology, settle it.
• Why it counts : Miss the call and you either operate on a harmless lump or let a cancer slip. Big gap.

That’s the whole reason knowing tumour and cancer aren’t interchangeable changes how you read your own diagnosis.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. He’s handled every kind of adrenal growth, from pheochromocytomas and Conn syndrome adenomas to adrenocortical carcinoma. The workup comes first, full biochemical and imaging evaluation, before surgery is even on the table. What the tumour is doing decides the plan, not its size alone. That’s where adrenal surgery is won or lost.

Pheochromocytomas are a clear example. The hormonal blockade in the weeks before surgery is what keeps the operation from turning into a cardiovascular emergency. Without that prep, a benign tumour can turn dangerous fast. Handled properly, robotic and laparoscopic adrenalectomy means small incisions and a recovery open surgery can’t touch.

References

1. Adrenal tumour malignancy risk evaluation — National Library of Medicine
2. Adrenocortical carcinoma overview — National Cancer Institute

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

Kidney cancer can involve both kidneys, but this is far less common than patients fear when they first hear the diagnosis. Bilateral renal cell carcinoma accounts for roughly 2 to 4 percent of all kidney cancer cases. What most patients don’t realise is that both kidneys having cancer doesn’t always mean one has spread to the other. In many cases the two tumours developed completely independently. The cause matters more than the count.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Bilateral kidney cancer is not one clinical scenario. Some patients have two independent primary tumours that each developed on their own. Others carry a hereditary mutation that predisposes both kidneys to develop multiple lesions over time. These are different problems that need different plans and the workup has to establish which situation you are actually in before any surgery is discussed.”

Three distinct situations lead to bilateral kidney involvement and they are not the same thing.

• Hereditary syndromes: Von Hippel-Lindau disease, hereditary papillary renal cell carcinoma and Birt-Hogg-Dube syndrome all predispose both kidneys to develop tumours independently. This is not metastasis. Both kidneys carry the same germline mutation and develop lesions separately. These patients tend to present younger, with multiple bilateral tumours and often a family history of kidney cancer.
• Synchronous bilateral sporadic RCC: Two separate primary tumours found simultaneously in both kidneys in a patient with no hereditary syndrome. Occurs in roughly 1 to 2 percent of sporadic cases. Genomic studies confirm these tumours develop independently. Not one spreading to the other.
• Metachronous bilateral disease: A second primary tumour appearing in the contralateral kidney months or years after the first was treated. Occurs in about 0.4 percent of RCC patients. Distinguishing this from metastasis requires staging and careful imaging because the treatment approach differs completely.
• True contralateral metastasis: RCC can occasionally spread to the opposite kidney but this is uncommon. More typically it spreads to lung, bone, liver and brain before involving the contralateral kidney. Identifying whether both kidneys carry independent primaries or one is a metastatic deposit is essential before any plan is made.

For patients with bilateral kidney cancer needing nephron-sparing minimally invasive surgery, robotic cancer surgery enables precise partial nephrectomy that preserves renal function while achieving clear surgical margins.

Preserving kidney function is the surgical priority. Losing both kidneys means lifelong dialysis.

• Partial nephrectomy over radical: Nephron-sparing surgery removes the tumour while preserving functioning renal tissue in both kidneys. For bilateral disease this isn’t a compromise, it is the clinical standard. Both kidneys are preserved wherever technically feasible.
• Staged surgical approach: Operating on both kidneys simultaneously carries significant physiological risk. The more threatening side is addressed first. Full renal recovery is confirmed before the contralateral kidney is operated. Timing depends on tumour size, growth rate and baseline renal function.
• Systemic therapy for hereditary disease: VHL patients with multiple bilateral lesions are increasingly managed with belzutifan, an HIF-2alpha inhibitor approved specifically for VHL-related RCC. It allows treatment of multiple small tumours that would otherwise require repeated bilateral surgeries over years.
• Genetic testing for every bilateral case: Every patient with bilateral or multifocal kidney cancer needs genetic counselling referral. Identifying a hereditary syndrome changes the surgical strategy, the surveillance schedule, and alerts other family members who carry the same mutation risk without yet knowing it.

For patients wanting to understand how kidney cancer behaves when it advances beyond the kidney itself, our blog on metastatic kidney cancer explains the spread pattern and treatment options in detail.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs robotic and laparoscopic partial nephrectomy for kidney cancer, evaluates every bilateral or multifocal renal tumour for hereditary syndrome referral at the tumour board, and plans nephron-sparing surgery that protects long-term renal function alongside oncological clearance.

Bilateral kidney cancer is one of the situations where the surgical approach has to account for what the patient will live with for the next twenty years, not just what removes the cancer today. That balance between oncological adequacy and renal preservation is what high-volume specialist surgical oncology makes possible. Call +91 8104310753 to book your consultation.

References:

1. National Institutes of Health — Genetic Predisposition to Kidney Cancer: https://pmc.ncbi.nlm.nih.gov/articles/PMC5137802/
2. PubMed Central — Hereditary Renal Cancer Syndromes: https://pmc.ncbi.nlm.nih.gov/articles/PMC3872053/

Disclaimer: This blog is intended for educational and informational purposes only and does not substitute professional medical advice, diagnosis or treatment.

Gastric adenocarcinoma and gastrointestinal stromal tumour arise in the same organ but represent entirely distinct diseases. Separate cellular origins, separate molecular drivers, separate treatment protocols. Chemotherapy that works for stomach cancer has no activity in GIST. Imatinib that works for GIST has no role in gastric adenocarcinoma. The pathology report determines which treatment the patient receives, and getting that wrong has direct clinical consequences.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “GIST and gastric adenocarcinoma are two separate malignancies arising in the same anatomical location. Immunohistochemistry must confirm the diagnosis before any systemic treatment decision is made. Applying gastric chemotherapy to a GIST produces no response. The pathology drives everything here and it cannot be assumed.”

The distinction runs across cellular origin, molecular biology, surgical scope and systemic treatment response.

• Cellular origin: Gastric adenocarcinoma arises from the glandular epithelium of the mucosal lining. GIST arises from the interstitial cells of Cajal within the muscle wall. Different cell. Entirely different tumour biology.
• Molecular driver: Gastric cancer is driven by H. pylori, HER2 amplification and chromosomal instability. GIST is driven by KIT or PDGFRA tyrosine kinase mutations in over 85 percent of cases — that targetable mutation is what makes imatinib work. Gastric cancer has nothing equivalent.
• Lymph node involvement: Gastric adenocarcinoma spreads to regional lymph nodes consistently, making D2 lymphadenectomy standard. GIST rarely involves lymph nodes at all. Dissecting them in a GIST resection adds morbidity with no oncological return.
• Chemotherapy response: FLOT, FOLFOX and DCF are active in gastric adenocarcinoma. GIST is chemoresistant. Standard cytotoxic chemotherapy has no meaningful activity in GIST and should not be used.

For patients with either diagnosis requiring minimally invasive surgical resection, robotic cancer surgery enables precise D2 lymphadenectomy for stomach cancer and margin-negative wedge resection for GIST.

• Surgical scope differs significantly: Gastric cancer needs D2 lymph node clearance because nodal metastasis determines both staging and prognosis. GIST needs only a clear surgical margin. Adding lymphadenectomy to a GIST resection is unnecessary and harmful.
• Imatinib works only in GIST: It blocks the mutant KIT or PDGFRA driving tumour proliferation. High-risk GIST patients take it for three years after surgery and advanced disease responds in over 80 percent of cases. In gastric adenocarcinoma it has no role whatsoever.
• HER2 is gastric cancer territory: Around 15 to 20 percent of gastric adenocarcinomas overexpress HER2, qualifying those patients for trastuzumab alongside chemotherapy. In GIST, HER2 testing carries no clinical relevance.
• Both can occur together: GIST and gastric adenocarcinoma can present simultaneously in the same patient. Each needs independent pathological confirmation and its own treatment plan even when a single surgical operation addresses both.

For patients wanting to recognise early clinical warning signs that prompt the endoscopic investigations identifying these tumours, our blog on stomach cancer warning signs covers the symptom profile in clinical detail.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He has published clinical research on GIST and imatinib in locally advanced cases in Indian patients, performs robotic gastrectomy with D2 lymphadenectomy for gastric adenocarcinoma and margin-negative wedge resection for GIST, and presents every upper gastrointestinal tumour to the tumour board before treatment planning begins.

Misclassifying GIST as gastric adenocarcinoma is not a documentation error — it is a treatment error. Whether the patient receives imatinib or FLOT depends entirely on immunohistochemistry including CD117, DOG1 and HER2, and that distinction is confirmed at the first consultation at MACS Clinic. Call +91 8104310753 to book your consultation.

References:

1. National Institutes of Health — Imatinib Treatment for Gastrointestinal Stromal Tumour: https://pmc.ncbi.nlm.nih.gov/articles/PMC3837608/
2. PubMed Central — 2023 GEIS Guidelines for Gastrointestinal Stromal Tumors: https://pmc.ncbi.nlm.nih.gov/articles/PMC10467260/

Disclaimer: This blog is intended for educational and informational purposes only and does not substitute professional medical advice, diagnosis or treatment.

Colorectal cancer has traditionally been considered a disease of people above 50. That picture is changing. Indian data from tertiary cancer centres shows a rising proportion of cases in patients under 40. Some studies put that figure at 10 to 15 percent. In Western registries it’s under 5. The shift is real, the drivers are known, and the delay in diagnosis is the part that’s doing the most damage.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “I see young patients with colorectal cancer regularly now. People in their 30s who spent six months being told it was acidity or piles before anyone did a colonoscopy. The biology in young Indian patients is often more aggressive too, higher grade, more mucinous, presenting at a later stage simply because no one thought to investigate early. That has to change.”

The causes aren’t mysterious. They’re sitting on every dinner table and in every office chair.

• Ultra-processed food and low fibre intake: Traditional Indian diets carried fibre from lentils, vegetables and whole grains. Urban diets swapped that out for packaged, processed and fast food. Less fibre means slower bowel transit. Slower transit means longer carcinogen contact with the colonic wall. That’s the mechanism. It’s not complicated.
• Sedentary lifestyle and obesity: Central obesity and physical inactivity both raise colorectal cancer risk on their own. Put them together in a desk-bound 35-year-old with a rising BMI and the risk compounds. Indian urban data tracks this exactly.
• Smoking and alcohol: Independent risk factors, both. Rates among Indian men under 40 have climbed. Cancer biology in smokers runs more aggressive. Presentation tends to be later stage. Two bad combinations in one.
• Genetic factors underdiagnosed: Lynch syndrome and familial adenomatous polyposis drive early-onset colorectal cancer. Both run in families. Most young Indian patients never get tested. The hereditary proportion of early-onset cases is significant. Finding it changes the surgical plan. It also means siblings and children carry the same risk and need to know.

For patients at high risk who need surgical treatment, robotic cancer surgery delivers precision colorectal resection with faster recovery than open surgery.

The gap is not information. It’s action.

• Don’t dismiss rectal bleeding: In India, bleeding is almost automatically called piles. Piles are common. Cancer is not rare either. A colonoscopy takes 30 minutes. When bleeding persists, that 30 minutes is not optional.
• Screen earlier with family history: Average risk? Start at 40. First-degree relative with colorectal cancer? Start at 40 or 10 years before their diagnosis age, whichever comes first. That rule exists because hereditary colorectal cancer runs ahead of the standard screening age.
• Lynch syndrome warrants genetic counselling: Colorectal cancer under 50 combined with family history of bowel, uterine or ovarian cancer. That pattern needs a genetics referral. Finding Lynch syndrome changes surgical planning. More importantly, it tells siblings and children they’re at risk before they get sick.
• Change the diet before symptoms appear: More fibre. Less processed meat. Less red meat. Move more. Stay in a healthy weight range. None of this eliminates risk completely. But it shifts the odds, and starting at 30 shifts them more than starting at 50.

For a practical breakdown of what early colorectal symptoms actually look like and when they need investigation, our blog on early detection rectal cancer covers the warning signs in detail.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs robotic and laparoscopic colorectal cancer surgery including intersphincteric resection for low rectal cancers, integrates genetic risk assessment into the young patient consultation, and presents every colorectal cancer case to the tumour board before the surgical plan is confirmed.

Young patients with colorectal cancer deserve surgical precision, but they also deserve a conversation about genetic risk, fertility implications of pelvic surgery and long-term quality of life. That conversation happens at MACS Clinic before the operation, not after it. Call +91 8104310753 to book your consultation.

References:

1. National Institutes of Health — The Increase of Early-Onset Colorectal Cancer: https://pmc.ncbi.nlm.nih.gov/articles/PMC12966572/
2. PubMed Central — Focusing on Colorectal Cancer in Young Adults (Review): https://pmc.ncbi.nlm.nih.gov/articles/PMC10729308/

Disclaimer: This content is for general awareness about the rising incidence of colorectal cancer in younger adults. It is not a substitute for a clinical consultation, colonoscopy recommendation or personalised cancer screening advice. If you or a family member have symptoms or a family history of colorectal cancer, consult a surgical oncologist for a proper evaluation.

Only 15 to 20 percent of pancreatic cancer patients qualify for Whipple surgery. The rest have disease that has spread too far or involves blood vessels that make surgery unsafe. Candidacy comes down to three things: where the tumour sits, whether it has grown into major vessels, and whether the patient is fit enough for one of the most demanding operations in oncology.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Whipple surgery is the only operation that offers a realistic chance of cure in pancreatic cancer. But it only works when the cancer is truly resectable, meaning it hasn’t wrapped around the superior mesenteric artery or vein in a way that makes clear margins impossible. The staging assessment before the operation is as important as the operation itself. Getting that wrong in either direction, operating when you shouldn’t or not operating when you should, changes outcomes dramatically.”

Four criteria define resectability. All four need to be met.

• Cancer in the head of the pancreas: The Whipple procedure removes the head of the pancreas, the duodenum, part of the bile duct, the gallbladder and nearby lymph nodes. It’s the right operation for cancers in the pancreatic head. Body and tail cancers need distal pancreatectomy, not Whipple.
• No involvement of major vessels: The superior mesenteric artery and superior mesenteric vein run directly behind the pancreatic head. Cancer that has encased the artery makes clear margins impossible. Abutment alone may still be resectable. Encasement is not.
• No distant metastasis: Liver metastases, peritoneal spread or lung involvement make Whipple palliative at best. Staging CT and PET-CT must confirm disease is localised before the operation is planned.
• Patient fitness: Whipple is a six to eight hour operation with significant physiological demand. Cardiac reserve, lung function, nutritional status and performance score all feed into the fitness assessment. An unfit patient with a resectable tumour may not be a surgical candidate until fitness improves.

For patients whose pancreatic cancer requires minimally invasive surgical removal, robotic cancer surgery includes robotic pancreaticoduodenectomy, available at select high-volume centres with surgeons trained in robotic pancreatic surgery.

Not all unresectable presentations are permanently unresectable.

• Borderline resectable: The tumour abuts but hasn’t encased the superior mesenteric vessels. Surgery is technically possible but margins are at risk. Neoadjuvant chemotherapy, typically FOLFIRINOX or gemcitabine-nab paclitaxel, is given first to shrink the tumour away from the vessels before re-staging.
• Response-guided restaging: After 4 to 6 months of neoadjuvant chemotherapy, CT and sometimes PET-CT reassess whether vessel clearance has improved. Patients who downstage to clearly resectable territory can proceed to Whipple. Not all do.
• Locally advanced but not metastatic: Cancer that has grown significantly into the SMA or coeliac axis. Technically unresectable in most cases. Systemic chemotherapy and sometimes radiation are used. A small proportion downstage enough to revisit surgery.
• Palliative surgery for symptoms: Patients who aren’t Whipple candidates can still have biliary bypass or gastric bypass surgery to relieve jaundice or gastric outlet obstruction without removing the tumour.

For patients with pancreatic cancer where Whipple isn’t possible, our blog on pancreatic cancer survival explains what the outlook looks like across stages and treatment types.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He is among the very few surgeons in India performing robotic Whipple surgery, assesses every pancreatic cancer case at the tumour board before confirming resectability, and coordinates neoadjuvant chemotherapy planning for borderline resectable cases with the medical oncology team.

Whipple surgery is one of the hardest operations to do well. Surgical volume, anatomical familiarity with the pancreatic head and its vascular relationships, and the team behind the surgeon all determine whether a technically demanding resection ends with clear margins and a patient who recovers. That’s the gap between a centre that does this occasionally and one that does it at real volume. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

In oral cancer surgery, neck dissection is part of the same operation in most cases, not a separate procedure. Oral cancers spread to the neck lymph nodes early, often before anything is visible or palpable. Waiting until nodes are clinically positive before clearing them is a risk the evidence doesn’t support. For most tumours at stage T2 and above, and for many T1 tumours with depth of invasion above 4mm, neck dissection happens at the same time as the primary surgery.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Neck dissection with oral cancer surgery is not a question of whether but when and how much. Oral cancers use the lymphatic pathways to the neck before they announce themselves clinically. Waiting for nodes to appear before addressing them is too late in most cases. The decision about which levels to clear and whether both sides need addressing is made at the tumour board, not in the operating room.”

Stage, depth and clinical status all feed into the decision.

• Elective neck dissection: Done when the neck appears clinically clear on examination and imaging but the tumour’s depth of invasion, size or location puts the risk of occult nodal spread above 15 to 20 percent. That threshold is based on the landmark D’Cruz NEJM trial. Levels I to III are cleared as standard.
• Therapeutic neck dissection: Done when nodes are already clinically positive on examination, CT or PET-CT. More extensive. Usually includes levels I to IV, sometimes V depending on which nodes are involved and where.
• Depth of invasion trigger: Tumours with depth of invasion above 4mm carry enough risk of occult nodal spread that elective neck dissection is standard even in early stage oral cancers where the neck appears clear. Depth measured on MRI or post-resection pathology.
• Contralateral neck: Midline tumours, tongue cancers crossing the midline and floor of mouth cancers often spread to both sides of the neck. Bilateral neck dissection is performed in the same operation when staging and tumour location indicate it.

For patients choosing minimally invasive surgery for the neck component of oral cancer treatment, robotic cancer surgery includes the MIND technique, a robotic infraclavicular approach to neck dissection that avoids any visible scar on the neck.

Structured, level-by-level lymph node clearance. Not blind excision.

• Levels cleared: The neck is divided into levels I to V. Oral cancer most commonly spreads to levels I, II and III. These are removed in every elective neck dissection. Levels IV and V are added when clinical findings or frozen section dictates.
• Structures preserved: The spinal accessory nerve controlling shoulder movement, the internal jugular vein and the sternocleidomastoid muscle are preserved unless cancer has directly invaded them. Unnecessary sacrifice causes function loss the patient didn’t need.
• Same operation as primary: Neck dissection happens simultaneously with oral cavity resection in almost every case. Two separate operations and two recoveries when one achieves both is not how experienced surgical oncology teams work.
• Frozen section intraoperatively: Suspicious nodes are sent for frozen section during the operation. Positive findings can prompt extension of the dissection to additional levels before the patient leaves theatre.

For a complete explanation of what neck dissection surgery involves and what recovery looks like, our blog on neck dissection surgery covers the full procedure in detail.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs oral cancer resection with integrated neck dissection, MIND robotic infraclavicular neck dissection for patients wanting no neck scar, and TORS for accessible oropharyngeal tumours, with every case reviewed by the tumour board before the surgical plan is confirmed.

The decision about levels, bilaterality and surgical approach in neck dissection is built on volume. Surgeons who do this every week read the anatomy differently from surgeons who do it occasionally, and that difference shows in recurrence rates and functional outcomes. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.